AZMARDA Tablets (Sacubitril/Valsartan)
Table of Content
Azmarda is a brand of sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) presently approved for the treatment of heart failure with reduced ejection fraction (HFrEF). The brand card contains key information about this molecule on its composition, indication, dosage and administration, contraindications etc. in a reader-friendly format.
Heart failure (HF) is the final step in different cardiovascular pathologies such as ischemic heart disease, hypertension and valvular heart disease. It is a major health problem associated with a significant morbidity and mortality not only in industrialized nations but also in the developing world. About 26 million adults worldwide are living with HF, leading some to describe it as a global pandemic.
According to available estimates, around 17–45% of patients admitted to a hospital with HF die within 1 year of admission. Despite considerable advances in the medical treatment, rates of death and hospitalizations for HF remain high which also impose a considerable economic burden on patients. Thus, there is a great medical and fiscal need to develop newer strategies to improve survival as well as prevent hospitalizations and reduce readmissions.
Sacubitril/valsartan is the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) that contains the neprilysin inhibitor prodrug sacubitril and the angiotensin-II receptor antagonist valsartan in a salt complex (molar ratio 1:1). It offers simultaneous blockade of the enzyme neprilysin, and the renin angiotensin aldosterone system, subsequently resulting in vasodilation, natriuresis/diuresis, and decrease in myocardial fibrosis and hypertrophy. In the landmark Prospective Comparison of ARNI with ACE inhibitors (ACEi) to Determine Impact on Global Mortality and Morbidity in Hart Failure (PARADIGM-HF) trial – the largest ever clinical trial in HF till date, sacubitril/valsartan exhibited significantly greater reduction in cardiovascular death and HF hospitalization as compared to the angiotensin converting enzyme inhibitor (ACE-i), enalapril in patients with HF with reduced ejection fraction. It was well tolerated overall and did not exhibit any major safety concerns. The most common side effects which may be observed with sacubitril/valsartan are hypotension, hyperkalemia and renal dysfunction.
Cipla has recently launched sacubitril/valsartan under the brand name AZMARDA. It is available in three strengths 50 mg, 100 mg and 200 mg. Launching AZMARDA is Cipla’s step towards making this latest blockbuster agent available to the practicing clinicians to aid the initiative of “Combat Heart Failure”